Tema ETFs LLC Takes $1.03 Million Position in Kura Oncology, Inc. $KURA

Posted by Stanley Muller on Aug 14th, 2026

Tema ETFs LLC acquired a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 93,761 shares of the company’s stock, valued at approximately $1,029,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio acquired a new position in shares of Kura Oncology during the first quarter valued at $143,000. Legal & General Group Plc increased its holdings in shares of Kura Oncology by 35.1% during the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after purchasing an additional 18,930 shares during the period. Rhumbline Advisers raised its stake in shares of Kura Oncology by 13.0% during the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after purchasing an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Kura Oncology by 244.5% during the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after purchasing an additional 165,189 shares in the last quarter.

Kura Oncology Trading Up 1.5%

Shares of Kura Oncology stock opened at $10.09 on Friday. The business has a fifty day simple moving average of $10.17 and a 200-day simple moving average of $9.32. Kura Oncology, Inc. has a fifty-two week low of $6.35 and a fifty-two week high of $12.49. The firm has a market cap of $895.69 million, a price-to-earnings ratio of -2.99 and a beta of 0.38. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 169.73% and a negative net margin of 384.30%.The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. On average, equities analysts forecast that Kura Oncology, Inc. will post -3.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KURA has been the subject of a number of recent analyst reports. Jefferies Financial Group set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, June 15th. Finally, Wells Fargo & Company set a $24.00 target price on Kura Oncology in a report on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $25.62.

Read Our Latest Stock Report on KURA

Insider Activity

In related news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.60% of the stock is owned by corporate insiders.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: Quarterly results beat expectations: Kura reported a second-quarter loss of $0.77 per share, narrower than the consensus estimate of a $0.88 loss. Revenue of $20.87 million also exceeded the $20.16 million analyst forecast. Kura Oncology Reports Q2 Loss, Beats Revenue Estimates
Positive Sentiment: KOMZIFTI sales grew strongly: Ziftomenib generated $9.1 million in net product revenue, up 57% from the first quarter, while new patient starts increased 35% to approximately 115. The commercial ramp provides an important source of near-term revenue growth. Kura Oncology Reports Second Quarter 2026 Financial Results
Positive Sentiment: Analyst confidence increased: Wedbush raised its Kura price target from $36 to $38 and assigned an “outperform” rating. The target implies substantial upside from the stock’s recent level, supporting the positive trading reaction. Wedbush Raises Kura Oncology Price Target
Neutral Sentiment: Future milestones remain ahead: Management outlined potential collaboration revenue of $90 million to $110 million in 2027 and is targeting topline results from the KOMET-017 study in 2028. These milestones could materially affect valuation, but they remain dependent on execution and clinical outcomes. Kura Outlines 2027 Collaboration Revenue and 2028 Trial Timeline
Negative Sentiment: Kura remains loss-making: The company’s quarterly loss increased from $0.75 per share a year earlier, and it continues to report deeply negative margins and returns on equity. Sustained commercialization costs and dependence on future clinical success remain key risks. Kura Oncology Earnings Results and Conference Call

About Kura Oncology

(Free Report)

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.